Type 2 Diabetes

New data from ENDO 2020 has uncovered a potential link between loss of meibomian glands and increased blood glucose levels.

Results of the 5-year Protocol T extension study are offering insight into the differences in real-world treatment and study protocol with anti-VEGF treatments.

A look at the state of cardiometabolic care based on research at ACC.20/WCC from a fourth-year medical student.

How new DAPA-HF findings continue to build the SGLT2 inhibitors' cardiovascular portfolio.

African American and Hispanic patients use devices for type 1 diabetes less than Caucasian patients.

Glucagon-like receptor agonists did not reduce the rate of hospitalization for heart failure as much as SGLT2 inhibitors did.

For every 1% higher baseline A1C, there was a 0.06 lower standardized CASI z-score.

A new subanalysis from the TWILIGHT trial found benefits of ticagrelor monotherapy remained consistent across both diabetics and nondiabetics.

Discussing the impact of rivaroxaban 2.5 mg BID plus aspirin in diabetics versus nondiabetics from the COMPASS trial with Deepak Bhatt, MD.

A board member of the college highlights 4 highly anticipated trials coming out of ACC 2020.

A study’s proposed findings of increased coronavirus risk shows how presenting half of a fact can influence our care during a pandemic.

An ACC board member explains the major cardiology college's decision to move the meeting online during the COVID-19 pandemic.

The Mount Sinai expert and ACC late-breaking presentation panelist highlights her most anticipated trial data and discussions in the upcoming meeting.

A new study of more than 30k Swedish men is shedding light on associations between early puberty and risk of T2D.

Muthiah Vaduganathan, MD, MPH, discusses how research of the add-on drug class will continue to evolve into 2021.

What's known about at-risk cardiometabolic patient care during the pandemic.

Transplanted hearts are protected by the diabetes drug Metformin, when the recipient is diabetic a study in the Journal of the American College of Cardiology finds.

A discussion with a Brigham and Women's Hospital cardiologist on the research of the add-on cardiometabolic drug class.

Technology, data, and community partnerships can help improve the overall health of patients with chronic health conditions.

Telehealth tools can identify someone whose symptoms are worsening and connect them to a medical professional.

Physicians and patients should continue treatment with their usual anti-hypertensive or diabetes management therapy, says the European Society of Cardiology (ESC).  There is no evidence that ACEi or ARBs, drugs which upregulate Angiotensin Converting Enzyme (ACE), increase the risk of contracting COVID-19, the society said in a statement published March 13.

Digital tools like electronic health records play an important role in addressing care for patients with chronic health conditions.

Roy Schoenberg, MD, MPH, discusses the populations that can most benefit from using telehealth tools and Medicare reimbursement obstacles.

Patients with cardiovascular disease, respiratory disease, cancer and diabetes are at increased risk for contracting COVID-19 and have a worse prognosis, said the American College of Cardiology in a clinical bulletin released March 6.

A new study is diving into differences in long-term outcomes, including remission rates and weight loss, seen among patients undergoing RYGB and SG.